To assess the safety and to evaluate the ability of Lu-177-DOTATATE to improve upon progression-free survival (PFS) at 6 months in patients with inoperable, SSTR positive PHEO/PGL by comparing PFS of patients treated with Lu-177-DOTATATE to historical controls from existing literature.